Literature DB >> 29529693

[Implementation of Hyperthermic Intrathoracic Chemotherapy (HITHOC) in Germany].

Michael Ried1, Hans-Stefan Hofmann1,2, Hendrik Dienemann3, Martin Eichhorn3.   

Abstract

INTRODUCTION: For several years, hyperthermic intrathoracic chemotherapy (HITHOC) has been performed in a few departments for thoracic surgery in a multimodality treatment regime in addition to surgical cytoreduction. Specific data about HITHOC in Germany are still lacking.
METHODS: Survey in written form to all departments of thoracic surgery in Germany. The objective is the evaluation of HITHOC with respect to number, indications, technique, perioperative protection measure and complications.
RESULTS: A total of 116 departments of thoracic surgery were contacted, with a return rate of 43% (n = 50). HITHOC was not performed in 33 departments, due to lack of resources or experience (n = 17), missing efficacy of the procedure (n = 8) and fear of excessive complication rates (n = 3). Since 2008, a total of 343 HITHOC procedures have been performed in 17 departments. Eight departments have their own perfusion machine, whereas the remaining departments borrow the perfusion machine. Indications were malignant pleural mesothelioma in all departments (n = 17), thymoma with pleural spread (n = 11) and secondary pleural carcinosis (n = 7). The HITHOC was performed in nearly all departments after closing the chest (n = 16), with a temperature of 42 °C (n = 12) and for 60 minutes (n = 15). Cisplatin was always used, either alone (n = 9) or in combination (n = 8). In all the participating departments, the aims of the HITHOC were improvement in local tumor control and prolonged recurrence-free and overall survival. Relevant HITHOC-associated complications were low.
CONCLUSIONS: HITHOC is performed in at least 17 departments of thoracic surgery in Germany, and is widely standardised with protective measures and a low rate of complications. The aims of the HITHOC are improvement in local tumor control in pleural malignancies combined with prolonged overall survival and better quality of life. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29529693     DOI: 10.1055/a-0573-2419

Source DB:  PubMed          Journal:  Zentralbl Chir        ISSN: 0044-409X            Impact factor:   0.942


  5 in total

1.  Clinical factors affecting the survival of patients diagnosed with non-small cell lung cancer and metastatic malignant pleural effusion, treated with hyperthermic intrathoracic chemotherapy or chemical talc pleurodesis: a monocentric, prospective, randomized trial.

Authors:  Athanasios Kleontas; Antonia Sioga; Niki Pandria; Nikolaos Barbetakis; Achilleas Lazopoulos; Ioannis Katsikas; Christos Asteriou; Dimitrios Paliouras; Efstathios Kamperis; Dimitrios Ikonomou; Theodora Papamitsou; Dimitrios Filippou; Chariklia Destouni; Louiza Ikonomou; Konstantinos Zarogoulidis; Kostas Papagiannopoulos
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

Review 2.  Narrative review of theoretical considerations regarding HITHOC between past and future.

Authors:  Tamas F Molnar; Andras Drozgyik
Journal:  Ann Transl Med       Date:  2021-06

3.  Better effect of intrapleural perfusion with hyperthermic chemotherapy by video-assisted thoracoscopic surgery for malignant pleural effusion treatment compared to normothermic chemoperfusion of the pleural cavity.

Authors:  Yejun Cao; Qiying Zhang; Zhiyuan Huang; Zhengjun Chai; Jie Liu; Jinyi Wang; Zhengliang Sun; Tian Zhao; Guangxue Wang; Guohan Chen; Yang Han; Qinchuan Li; Xuan Hong
Journal:  Cancer Med       Date:  2021-12-01       Impact factor: 4.452

4.  Protocol of a retrospective, multicentre observational study on hyperthermic intrathoracic chemotherapy in Germany.

Authors:  Till Markowiak; Michael Koller; Florian Zeman; Gunnar Huppertz; Hans-Stefan Hofmann; Michael Ried
Journal:  BMJ Open       Date:  2020-07-20       Impact factor: 2.692

5.  Exposure to cisplatin in the operating room during hyperthermic intrathoracic chemotherapy.

Authors:  Till Markowiak; Michael Ried; Christopher Larisch; Dennis Nowak; Hans-Stefan Hofmann; Stefan Rakete
Journal:  Int Arch Occup Environ Health       Date:  2021-06-30       Impact factor: 3.015

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.